Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Clearmind Medicine Inc
(OP:
CMNDF
)
N/A
UNCHANGED
Last Price
Updated: 10:24 AM EST, Nov 11, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
7.900
Today's Range
N/A - N/A
52wk Range
N/A - N/A
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
This Psychedelics Company Begins Trading On NASDAQ With $7.5M Offering Then Reverse Stock Split
November 15, 2022
Psychedelics biotech firm Clearmind Medicine Inc.
Via
Benzinga
Clearmind Medicine Announces Pricing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market
November 14, 2022
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Performance
More News
Read More
Clearmind Medicine Featured in "Psychedelics Tonight," Streaming on ALTRD.TV
October 11, 2022
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Psychedelics Biotechs Clearmind And Mydecine Share Consolidation And Subscription Agreements
September 26, 2022
Via
Benzinga
SciSparc Ltd. Announces Initial Positive Results For The Cocaine Addiction Treatment Of Clearmind Medicine Inc.
June 07, 2022
Via
Benzinga
SciSparc And Clearmind Partnership Yields 3rd Patent Application For The Treating Of Obesity And Metabolic Syndromes
September 22, 2022
Via
Benzinga
Additional Positive Results Revealed In Cocaine Addiction Treatment Through SciSparc-Clearmind Collaboration
August 25, 2022
Via
Benzinga
SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.
August 25, 2022
Via
Benzinga
Psychedelic-Based Cocaine Addiction Treatment Study Showing Positive Results. This Is What We Know
August 24, 2022
Via
Benzinga
Psyched: Christie's Launches NFT Collection Supporting Psychedelic Science, Origin's Listing On CSE Gives Retail Investors Access To Private Companies
June 08, 2022
Via
Benzinga
The Bad And The Ugly? The State Of Excessive Alcohol Consumption In The U.S.
June 08, 2022
Via
Benzinga
Rising Cases Of Mental Health Disorders of Stress, Anxiety & Addiction Fueling Need for Central Nervous System Therapeutics
June 07, 2022
Via
FinancialNewsMedia
Exposures
COVID-19
SciSparc & Clearmind Medicine Team Up On Patent For Psychedelic Combination To Treat Cocaine Addiction
June 02, 2022
Via
Benzinga
SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields Another Patent Application for their Proprietary Psychedelic Combination to Treat Cocaine Addiction
June 02, 2022
Via
Benzinga
New Psychedelic-Based Alcohol Substitute Approved In India, Produced By Clearmind Medicine
June 01, 2022
Via
Benzinga
High Hopes For Alcohol Use Disorder Treatment: Clearmind's Successful Pre-IND Meeting With The FDA
May 26, 2022
Via
Benzinga
Psyched: Medical Psychedelics In Davos, Canadian Sen Does Psychedelics, Ei.Ventures & Mycotopia To Merge Into $383M Company
May 24, 2022
Via
Benzinga
Psychedelic Treatment For Alcoholism? Clearmind Medicine And SciSparc Collaboration Yields Positive Results
May 24, 2022
Via
Benzinga
Global Psychedelics Market Is Expected To Reach $8 Billion By 2029
May 24, 2022
Via
FinancialNewsMedia
Clearmind: Positive Preclinical Evidence For Flagship Psychedelic Molecule, Looks To Human Trials Before Year End
May 19, 2022
Via
Benzinga
Psyched: Compass, Atai And MindMed Release Q1 Earnings, Phase 3 MDMA Trial Closer To Completion, Enveric Splits Into Two Companies
May 17, 2022
Via
Benzinga
Has Clearmind Developed A Psychedelics-Based Drug That Can Treat Alcoholism? The FDA Is Interested
May 13, 2022
Via
Benzinga
SciSparc And Clearmind Reveal Potential To Reduce Alcohol Consumption With Psychedelic Treatment In New Patent Application
May 11, 2022
Via
Benzinga
SciSparc And Clearmind Medicine Inc. Collaboration Yields New Patent Application For Psychedelic Combination Treatment For Binge Behaviors
May 10, 2022
Via
Benzinga
Alcoholism & Psychedelics: Clearmind Trials Reveal Certain Psychedelics Help Reduce Alcohol Consumption In Mice
March 17, 2022
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.